JAMA Intern Med:抗胆碱能药物与痴呆风险增加有关

2015-01-29 小田 译 医学论坛网

许多药物具有抗胆碱效应。一般来说,抗胆碱能药物诱导的认知损害在停止应用后是可逆的。但一些研究显示,抗胆碱能药物可能与痴呆风险增加有相关性。美国学者探讨了累积抗胆碱能药物应用与痴呆风险较高的相关性。结果表明,较高水平的累积抗胆碱能药物应用与痴呆风险增加有相关性,医生应警惕这类药物的这一相关风险。相关论文2015年1月26日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。

许多药物具有抗胆碱效应。一般来说,抗胆碱能药物诱导的认知损害在停止应用后是可逆的。但一些研究显示,抗胆碱能药物可能与痴呆风险增加有相关性。美国学者探讨了累积抗胆碱能药物应用与痴呆风险较高的相关性。结果表明,较高水平的累积抗胆碱能药物应用与痴呆风险增加有相关性,医生应警惕这类药物的这一相关风险。相关论文2015年1月26日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。

该基于人群的前瞻性队列研究纳入了年龄在65岁及以上既往无痴呆的3434例受试者,所有受试者均每2年随访一次。利用电子药房配药数据确定累积抗胆碱能药量——过去10年的总标准治疗日剂量(TSDD)。最近的12个月的用药排除在外,以避免相关的前驱症状。用标准诊断原则诊断痴呆和阿尔茨海默病,用Cox比例风险模型统计学分析校正人口统计学特征、健康行为和健康状态(包括合并症)。

结果显示,最常用的抗胆碱能药物为三环类抗抑郁药、第一代抗组胺药和蕈毒素受体阻断剂。在中位随访的7.3年间,进展为痴呆的患者数为797例(23.2%),其中637例进展为阿尔茨海默病(79.9%)。可观察到痴呆和阿尔茨海默病的10年累积剂量相关性。对于痴呆来说,与不应用抗胆碱能药物相比,其累积药物应用TSDD为1—90、91—365、366—1095和>1095的校正危险比分别为0.92、1.19、1.23和1.54,对于阿尔茨海默病,研究者们也观察到相似的结果。次要分析、敏感性和事后分析结果也显示强烈的相关性。

原始出处:

Gray SL1, Anderson ML2, Dublin S3, Hanlon JT4, Hubbard R5, Walker R2, Yu O2, Crane PK6, Larson EB7.Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study.JAMA Intern Med. 2015 Jan 26. doi: 10.1001/jamainternmed.2014.7663. [Epub ahead of print]


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=94998, encodeId=28cb9499805, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94999, encodeId=c1f4949995f, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316665, encodeId=2b45131666593, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527378, encodeId=21c7152e378ba, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546075, encodeId=476f15460e589, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606387, encodeId=4277160638ea6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=)]
    2016-07-29 囚徒

    拜读

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=94998, encodeId=28cb9499805, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94999, encodeId=c1f4949995f, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316665, encodeId=2b45131666593, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527378, encodeId=21c7152e378ba, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546075, encodeId=476f15460e589, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606387, encodeId=4277160638ea6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=)]
    2016-07-29 囚徒

    拜读

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=94998, encodeId=28cb9499805, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94999, encodeId=c1f4949995f, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316665, encodeId=2b45131666593, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527378, encodeId=21c7152e378ba, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546075, encodeId=476f15460e589, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606387, encodeId=4277160638ea6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=94998, encodeId=28cb9499805, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94999, encodeId=c1f4949995f, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316665, encodeId=2b45131666593, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527378, encodeId=21c7152e378ba, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546075, encodeId=476f15460e589, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606387, encodeId=4277160638ea6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=)]
    2015-01-31 grace5704
  5. [GetPortalCommentsPageByObjectIdResponse(id=94998, encodeId=28cb9499805, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94999, encodeId=c1f4949995f, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316665, encodeId=2b45131666593, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527378, encodeId=21c7152e378ba, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546075, encodeId=476f15460e589, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606387, encodeId=4277160638ea6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=94998, encodeId=28cb9499805, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94999, encodeId=c1f4949995f, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a9a1661764, createdName=囚徒, createdTime=Fri Jul 29 01:09:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316665, encodeId=2b45131666593, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527378, encodeId=21c7152e378ba, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546075, encodeId=476f15460e589, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606387, encodeId=4277160638ea6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 31 00:36:00 CST 2015, time=2015-01-31, status=1, ipAttribution=)]